ArticleTherapeutic advances in hematology2018

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study.

Ching-Yuan Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.